NCT00036543已完成3 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of 10 Mg Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Abbott
- 入组人数
- 1,000
- 试验地点
- 457
- 主要终点
- The primary objective of this study is to evaluate safety and efficacy as measured by time-to-disease progression
研究概览
简要总结
This study is being done to evaluate the safety and efficacy of atrasentan in men with metastatic hormone-refractory prostate cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of prostate cancer.
- •Rising PSA while on hormonal therapy or following surgical castration.
- •Documented evidence of metastatic disease.
排除标准
- •Have received cytotoxic chemotherapy.
- •Have received opioid or narcotic medications (such as codeine or morphine) or radiation for pain caused by your prostate cancer in the last 6 months.
结局指标
主要结局
The primary objective of this study is to evaluate safety and efficacy as measured by time-to-disease progression
次要结局
未报告次要终点
研究者
研究点 (457)
Loading locations...
相似试验
已完成
3 期
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate CancerProstatic NeoplasmsNCT00036556Abbott941
已完成
3 期
Study of Immunotherapy to Treat Advanced Prostate CancerProstate CancerNCT00861614Bristol-Myers Squibb988
进行中（未招募）
3 期
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's TypeAgitationAlzheimer's Type DementiaNCT05397639Suven Life Sciences Limited375
已完成
不适用
Clinical Trial of a Medical Device "Device for Non-invasive Electromagnetic Therapy "TOR" in the Treatment of COVID-19"Coronavirus Infection COVID-19NCT05220579Concern GRANIT236
已完成
3 期
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)Non-Small-Cell LungNCT03456063Hoffmann-La Roche453